March 17, 2008 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it submitted a New Drug Application of a fixed dose combination tablet of Blopress® (generic name: candesartan cilexetil) and diuretic (generic name: hydrochlorothiazide) for treatment of hypertension to the Ministry of Health, Labour and Welfare in Japan.
Discovered by Takeda, Blopress is an angiotensin II[*] receptor blocker (“ARB”), which was launched in 1999 and became the first ARB with an indication of Chronic Heart Failure in Japan. Hydrochlorothiazide is classified as a thiazide diuretic and lowers the blood pressure by increasing the flow of urine, which results in volume depletion. It is considered that there is a synergistic anti-hypertensive effect by concominant therapy of ARB and diuretic.
[*] Angiotensin II is known as one of the potent vasopressor hormones.
“We believe that the fixed dose combination tablet of Blopress with diuretic will be able to offer the better control of blood pressure,” said Masaomi Miyamoto, Ph.D., general manager of Pharmaceutical Development Division of Takeda. “We expect that this New Drug Application lead to maximization of added value of Blopress.”
Takeda is persuing every possiblity of fixed dose combination for its product line, which will contribute to the patient’s improved compliance. Currently, the fixed dose combinations of; Actos® (generic name: pioglitazone HCl) which is a member of the thiazolidinedione class of "insulin-sensitizing" agents with sulfonylurea ?generic name: glimepiride HCl?, and Actos with biganide (generic name: metformin HCl) are being marketed in overseas.
No comments:
Post a Comment